SHR0302 and Steroid As First Line Therapy for Chronic GVHD

The purpose of this study is to evaluate the efficacy of SHR0302 in combination with Prednisone as first line therapy in patients with moderate to severe chronic graft-versus-host disease (GVHD).

Treatment: Once patients are diagnosed with chronic GVHD, the combination therapy should be initiated as soon as possible. 1. Prednisone: 1mg/kg/d po. Taper steroid every two weeks according to patient's response. 2. SHR0302 QD po. for at least 28 days. Indication for stopping SHR0302 treatment: 1. No response after SHR0302 treatment for 12 weeks. 2. Develop life-threatening complication. 3. ANC\<0.5×10e9/L or PLT\< 30×10e9/L.

Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years old and ≤ 70 years old, male or female;
* Patients receiving allogeneic peripheral blood stem cell transplantation for hematological diseases;
* The primary hematological malignancies are completely relieved and are expected to be stable for at least 3 months;
* Chronic GVHD that was first attacked after transplantation and at least 100 days after transplantation, reached a moderate or severe level by NIH classification;
* There was no previous systemic treatment (including in vitro illumination \[ECP\]);
* The patient may be receiving other immunosuppressive agents to prevent or treat acute GVHD, but if the subject receives prednisone to prevent or treat acute GVHD, it must be \<0.5 mg/kg/d or equivalent dose of other glucocorticoids;
* The chronic GVHD that has started hormone therapy does not exceed 72 hours;
* Karnofsky score \> 60 points;
* Patients must be able to understand and are willing to participate in the study and sign an informed consent form.

Exclusion Criteria:

* Can not tolerate prednisone dose 1mg / kg / d or equivalent dose of other glucocorticoids for the treatment of cGVHD;
* Receive any systemic treatment of cGVHD, except for corticosteroids that treat cGVHD within 72 hours prior to the signing of informed consent;
* Patients with GVHD overlap syndrome (NIH criteria);
* Treatment of acute GVHD has received other Jak inhibitors such as ruxolitinib;
* Pregnant or lactating women;
* The patient is judged by the investigator to have complications that may cause other risks;
* The patient is receiving other study medications;
* Patient blood routine: ANC \<1.0 × 109 / L or PLT \< 50 × 109 / L;
* Non-GVHD-related liver damage: the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio is more than 3 times normal or the direct bilirubin normal value is more than 3 times;
* Renal dysfunction: endogenous creatinine clearance (Ccr) \< 50mL/min or normal serum creatinine 1.5 times or more, regardless of hemodialysis treatment;
* Uncontrolled infections: hemodynamic instability associated with infection, or new signs or signs of infection, or new infections in imaging, persistent fever without symptoms or signs and cannot be ruled out Infected person
* People living with HIV;
* Active hepatitis B (HBV), active hepatitis C (HCV) requires antiviral therapy; patients with HBV activation risk refer to patients with hepatitis B surface antigen-positive or core antibody-positive patients who are not treated with anti-HBV;
* The patient's primary malignant disease recurs and the graft is rejected;
* Those who are allergic to known JAK inhibitors.